Value Stock Alert: 1 Global Healthcare Company Set to Rise

Bausch Health Companies Inc. (TSX:BHC)(NYSE:BHC) has an established line of products that positions the company to compete in all areas of the eye-health market.

| More on:
healthcare pharma

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more

Bausch Health Companies (TSX:BHC)(NYSE:BHC) is a global company whose mission is to improve people’s lives with healthcare products. The company develops, manufactures, and markets, primarily in the therapeutic areas of eye-health, gastroenterology (GI) and dermatology, a broad range of branded pharmaceuticals, generic pharmaceuticals, over-the-counter (OTC) products, and medical devices. These are marketed directly or indirectly in approximately 100 countries.

The company’s portfolio of products falls into four operating and reportable segments. The Bausch and Lomb segment focuses on vision care, surgical, and consumer and ophthalmology products. The Salix segment consists of sales of GI products. The ortho-dermatologics segment consists of sales of dermatological products and global sales of Solta medical aesthetic devices. The diversified products segment consists of sales of pharmaceutical products in the areas of neurology and certain other therapeutic classes, and dentistry products.

Global vision care business

The company’s Bausch and Lomb segment includes a global eye-health business and an international medical prescription business. The global Bausch and Lomb eye-health business includes the global vision care, surgical, and consumer and ophthalmology prescription products, which, in aggregate, accounted for approximately 41%, 42%, and 43% of the company’s revenues for 2020, 2019, and 2018, respectively.

Bausch’s international prescription business includes sales in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East of branded pharmaceutical products, branded generic pharmaceutical products and OTC products, which, in aggregate, accounted for approximately 14%, 13%, and 13% of the company’s revenues for 2020, 2019, and 2018, respectively.

Fast-growing eye-health market

Bausch’s global Bausch and Lomb business is a fully integrated eye-health business, which is critical to maintaining and developing the company’s position in the global eye-health market. As a fully integrated eye-health business with a 165-year legacy, Bausch and Lomb has an established line of contact lenses, intraocular lenses, and other medical devices, surgical systems and devices, vitamin and mineral supplements, lens care products, prescription eye-medications, and other consumer products that position the company to compete in all areas of the eye-health market.

As part of the company’s global Bausch and Lomb business strategy, Bausch continually looks for key trends in the eye-health market to meet changing patient needs and identify areas for investment and growth. For instance, one of the trends the company sees is the increasing rate of myopia and, importantly, myopia as a potential risk factor for glaucoma, macular degeneration, and retinal detachment.

Exciting product development

Research indicates an increased demand for new eye-health products that address conditions brought on by factors, such as increased screen time, lack of outdoor activities, and academic pressures, as well as conditions brought on by an aging population. To supplement the well-established Bausch and Lomb product lines, the company continues to identify new products tailored to address key trends, which it develops internally to generate organic growth.

Bausch also licenses selective molecules and technology to leverage the company’s own research expertise through product development. Recent product launches include daily disposable contact lenses, lenses for eye redness treatment, pressure lowering eye drop for patients with angle glaucoma, and vitamins to protect the eye from stressors such as sunlight and blue light emitted from digital devices.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Nikhil Kumar has no position in any of the stocks mentioned. Tom Gardner owns shares of Bausch Health Companies. The Motley Fool owns shares of and recommends Bausch Health Companies.

More on Investing

energy oil gas
Dividend Stocks

2 High-Yield Energy Stocks to Buy as Recession Approaches

Energy stocks such as TC Energy and Canadian Natural Resources allow investors to generate income even in recessionary times.

Read more »

green power renewable energy
Dividend Stocks

3 Top Dividend Stocks to Drive Your Passive Income

These three high-yielding, safe dividend stocks could boost your passive income.

Read more »

Dial moving from 4G to 5G
Tech Stocks

TFSA Investors: 2 Canadian Stocks With Unbelievable Staying Power 

Amid economic uncertainty, investors look for stocks that can thrive in any crisis and grow long term. Here are two…

Read more »

protect, safe, trust
Dividend Stocks

TFSA Wealth: How to Earn $363 in Monthly Passive Income for Life

Canadian investors can harness the power of the TFSA to generate steady tax-free passive income for decades.

Read more »

Canadian Dollars
Dividend Stocks

TFSA Millionaire: How to Turn $40,000 Into $1.2 Million for Retirement

Here's how TFSA investors are using the power of compounding to buy top Canadian dividend stocks to build retirement wealth.

Read more »

potted green plant grows up in arrow shape
Stocks for Beginners

3 Superb Income and Growth Stocks for Every Portfolio

The market is full of superb income and growth stocks, but not all belong in your portfolio. Here are three…

Read more »

stock market
Stocks for Beginners

Worried About Stagflation? 2 Canadian Stocks for All Market Cycles 

Stagflation delays economic recovery. You can keep your portfolio stagflation ready with these Canadian stocks that are suitable for all…

Read more »

exchange traded funds
Stocks for Beginners

Why BMO’s Global Infrastructure ETF Is the Only TSX Stock You Need

BMO Global Infrastructure Index ETF (TSX:ETF) is the only TSX stock you need for passive income, solid cash flow, and…

Read more »